GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » PB Ratio

Janux Therapeutics (Janux Therapeutics) PB Ratio : 8.39 (As of May. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), Janux Therapeutics's share price is $62.43. Janux Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $7.45. Hence, Janux Therapeutics's PB Ratio of today is 8.39.

The historical rank and industry rank for Janux Therapeutics's PB Ratio or its related term are showing as below:

JANX' s PB Ratio Range Over the Past 10 Years
Min: 0.8   Med: 1.75   Max: 8.4
Current: 8.38

During the past 5 years, Janux Therapeutics's highest PB Ratio was 8.40. The lowest was 0.80. And the median was 1.75.

JANX's PB Ratio is ranked worse than
86.27% of 1311 companies
in the Biotechnology industry
Industry Median: 2.46 vs JANX: 8.38

During the past 12 months, Janux Therapeutics's average Book Value Per Share Growth Rate was -3.40% per year.

Back to Basics: PB Ratio


Janux Therapeutics PB Ratio Historical Data

The historical data trend for Janux Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics PB Ratio Chart

Janux Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 2.22 1.71 1.44

Janux Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 1.63 1.66 1.33 1.44

Competitive Comparison of Janux Therapeutics's PB Ratio

For the Biotechnology subindustry, Janux Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Janux Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's PB Ratio falls into.



Janux Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Janux Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=62.43/7.445
=8.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Janux Therapeutics  (NAS:JANX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Janux Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Janux Therapeutics (Janux Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Executives
Tighe Reardon 10 percent owner, officer: Acting Chief Financial Officer C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Avalon Ventures Xi, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter director, 10 percent owner C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter officer: Chief Technical Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson officer: Chief Strategy Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Capital Gp Vii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alana B. Mcnulty director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051

Janux Therapeutics (Janux Therapeutics) Headlines

From GuruFocus